F.D.A. Rejects Closely Watched Lung Cancer Drug From China
The U.S. Food and Drug Administration declined to approve ivonescimab, a bispecific antibody targeting PD-1 and VEGF developed by Akeso and licensed by Summit Therapeutics, for previously treated EGFR-mutated non-small cell lung cancer. The rejection follows the HARMONI-2 trial's failure to meet its primary overall survival endpoint despite showing progression-free survival benefit. Summit shares fell sharply on the news. The decision halts the first U.S. approval attempt for a PD-1/VEGF bispecific and leaves the drug's U.S. path uncertain.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ FDA rejected Summit Therapeutics' Biologics License Application for ivonescimab in previously treated EGFR-mutated non-small cell lung cancer.
- ✓ The HARMONI-2 trial did not meet its primary overall survival endpoint despite showing progression-free survival benefit.
- ✓ Ivonescimab is a bispecific antibody targeting PD-1 and VEGF, originally developed by Akeso and licensed by Summit for ex-China rights.
- ✓ Summit Therapeutics stock fell significantly following the FDA rejection announcement.
What changed
FDA issued a complete response letter rejecting the Biologics License Application for ivonescimab in pretreated EGFR-mutant NSCLC.
Live updates
-
FDA rejects Summit's ivonescimab for EGFR-mutant lung cancer
The U.S. Food and Drug Administration declined to approve ivonescimab, a bispecific antibody targeting PD-1 and VEGF developed by Akeso and licensed by Summit Therapeutics, for previously treated EGFR-mutated non-small cell lung cancer. The rejection follows the HARMONI-2 trial's failure to meet its primary overall survival endpoint despite showing progression-free survival benefit. Summit shares fell sharply on the news. The decision halts the first U.S. approval attempt for a PD-1/VEGF bispecific and leaves the drug's U.S. path uncertain.
Why it matters
Ivonescimab was closely watched as a potential first-in-class PD-1xVEGF bispecific and a major China-originated oncology candidate for the U.S. market. The FDA's complete response letter cites insufficient overall survival data from the single pivotal trial conducted in China. This puts the broader PD-1/VEGF class on notice that progression-free survival alone may not support approval in this setting. Summit must now decide whether to pursue additional trials or seek approval in other indications.
What is confirmed
- FDA rejected Summit Therapeutics' Biologics License Application for ivonescimab in previously treated EGFR-mutated non-small cell lung cancer.
- The HARMONI-2 trial did not meet its primary overall survival endpoint despite showing progression-free survival benefit.
- Ivonescimab is a bispecific antibody targeting PD-1 and VEGF, originally developed by Akeso and licensed by Summit for ex-China rights.
- Summit Therapeutics stock fell significantly following the FDA rejection announcement.
Still unconfirmed
- Ivonescimab could still seek approval in other indications or jurisdictions outside the United States.
What to watch next
- Summit's formal regulatory response and plans for additional trials or data generation
- FDA review of other PD-1/VEGF bispecific candidates in development
- Akeso's continued development of ivonescimab in China and other global markets
confidence 94%Sources used for this update (21)
- www.nytimes.com — The New York Times - Breaking News, US News, World News and Videos
- stocktwits.com — Stocktwits - Stock Market Live Quotes, Social Community...
- www.foxbusiness.com — Great Business Leaders in America & Around the World | Fox Business
- www.scmp.com — The EU’s China dilemma: how to counter Beijing without alienating friends | South China Morning Post
- www.medicaldaily.com — Salmonella Found in All Eight Oyster Samples From Virginia's Closed Little Wicomico River as Case Counts Diverge
- www.ibtimes.co.uk — Leak Claims Donald Trump Will Order Post-Election 'Big Effort' Strike on Iran 'Within 96 Hours'
- cashwalklabs.io — GM will switch to Nasdaq from the NYSE on Nov. 17
- Fierce Pharma — FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
- Reuters — US FDA declines to approve Summit lung cancer drug after trial misses key survival goal
- Yahoo Finance — Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- Bloomberg.com — US FDA Rejects Summit’s China-Originated Lung Cancer Drug
- STAT — FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community